Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Federal judge blocks Massachusetts ban of new painkiller Zohydro

Posted: April 16, 2014

Drug maker Zogenix Inc., won another battle in its war to get its controversial painkiller Zohydro on the market. This week, a Massachusetts federal judge blocked plans by Massachusetts Gov. Deval Patrick to ban prescriptions and sales of the newly

Boys with autism more likely to have been exposed to SSRIs in womb

Posted: April 16, 2014

Boys born to women who took a type of antidepressant during pregnancy were three times more likely to be diagnosed with autism than boys who were not exposed to the drugs in utero, a new study has found. The greatest

Doctor raises red flags regarding heart risks with testosterone therapy

Posted: April 15, 2014

Testosterone replacement therapy may sound attractive with ads promising to build muscle mass and boost libido, but Low T therapy may not be all that it’s cracked up to be, warns Dr. Joe Littlejohn, a urologist at Orlando Health. It

Consumer Reports group pushes for warranties on artificial hips

Posted: April 14, 2014

Nearly a half-million Americans each year undergo hip replacement surgery, an invasive operation that requires weeks of rehabilitation. Typical hip implants can last 20 years or more before being replaced, but some have been shown to fail at a faster

Bayer files motion to dismiss some of its Mirena IUD lawsuits

Posted: April 14, 2014

Bayer Healthcare Pharmaceuticals is hoping to ditch some of the 450 lawsuits it faces over inadequate warnings for possible complications with its Mirena intrauterine device on the grounds that the cases have exceeded the statute of limitations. The Mirena IUD is

European drug regulators investigating heart attack, stroke, death risks with testosterone therapies

Posted: April 14, 2014

The European Medicines Agency (EMA) is reviewing the safety of testosterone therapy after studies showed the treatment increases the risk of strokes, heart attacks and death. The announcement comes three months after the U.S. Food and Drug Administration (FDA) launched a

Anti-seizure drug Stavzor linked to life threatening liver failure

Posted: April 13, 2014

The anti-seizure and mood-stabilizing drug Stavzor and its derivatives has been linked to serious and sometimes fatal liver failure, and the risk is even greater in children younger than age 2 and patients with mitochondrial disease. The Food and Drug

Study questions safety, effectiveness of anti-viral drug Tamiflu

Posted: April 12, 2014

Tamiflu, the medication given to treat and prevent the influenza virus, has little effect on complications of the flu, such as pneumonia, and is now known to cause psychiatric symptoms, kidney problems, diarrhea and vomiting, according to a new report

Merck offers $100 million to settle NuvaRing lawsuits

Posted: April 12, 2014

Plaintiff’s lawyers are meeting in Las Vegas this week to determine whether enough claimants opted in on a $100 million settlement offered by Merck & Co. for its contraceptive NuvaRing, which has been linked to life threatening blood clots.

FDA delays decision on diabetes inhaler to review possible cancer risks

Posted: April 11, 2014

The Food and Drug Administration (FDA) has delayed its decision about whether to approve Mannkind Corp.’s Afrezza, an inhaled insulin treatment for diabetes, due to concerns about an increased risk of lung cancer.